Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 8/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | CKS1B | P61024 | 2/20 | 0.36 |
| ▸ | SKP1 | P63208 | 2/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31713549 | 0.82 | RET (0.52) | RETJAK3GPR119NTRK1CRBN | |
| SCHEMBL16333288 | 0.81 | CKS1B (0.53) | RETGPR119CKS1BSKP1SKP2 | |
| SCHEMBL31401286 | 0.81 | RET (0.47) | RETJAK3GPR119NTRK1NR1H2 | |
| SCHEMBL31713408 | 0.79 | JAK3 (0.46) | RETJAK3GPR119NTRK1NR1H2 | |
| SCHEMBL31713817 | 0.78 | GPR119 (0.44) | RETJAK3GPR119TRPC6 | |
| SCHEMBL31713482 | 0.78 | RET (0.52) | RETJAK3GPR119CRBN | |
| SCHEMBL31713641 | 0.77 | JAK3 (0.44) | RETJAK3GPR119NTRK1NR1H2 | |
| SCHEMBL30125727 | 0.77 | RET (0.45) | RETJAK3GPR119CRBNCYP11B2 | |
| SCHEMBL30126244 | 0.76 | RET (0.44) | RETJAK3GPR119CRBNCYP11B2 | |
| SCHEMBL31396179 | 0.76 | RET (0.41) | RETJAK3GPR119CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |